Literature DB >> 26745040

Long Non-coding RNAs and Drug Resistance.

Jing-Jing Pan1, Xiao-Juan Xie, Xu Li, Wei Chen.   

Abstract

BACKGROUND: Long non-coding RNAs (lncRNAs) are emerging as key players in gene expression that govern cell developmental processes, and thus contributing to diseases, especially cancers. Many studies have suggested that aberrant expression of lncRNAs is responsible for drug resistance, a substantial obstacle for cancer therapy. Drug resistance not only results from individual variations in patients, but also from genetic and epigenetic differences in tumors. It is reported that drug resistance is tightly modulated by lncRNAs which change the stability and translation of mRNAs encoding factors involved in cell survival, proliferation, and drug metabolism. In this review, we summarize recent advances in research on lncRNAs associated with drug resistance and underlying molecular or cellular mechanisms, which may contribute helpful approaches for the development of new therapeutic strategies to overcome treatment failure.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26745040     DOI: 10.7314/apjcp.2015.16.18.8067

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  20 in total

Review 1.  Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism.

Authors:  Tomas Smutny; Lucie Hyrsova; Albert Braeuning; Magnus Ingelman-Sundberg; Petr Pavek
Journal:  Arch Toxicol       Date:  2020-11-09       Impact factor: 5.153

Review 2.  Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer.

Authors:  Marios A Diamantopoulos; Panagiotis Tsiakanikas; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

Review 3.  Long Noncoding RNA in Cancer: Wiring Signaling Circuitry.

Authors:  Chunru Lin; Liuqing Yang
Journal:  Trends Cell Biol       Date:  2017-12-20       Impact factor: 20.808

4.  ERINA Is an Estrogen-Responsive LncRNA That Drives Breast Cancer through the E2F1/RB1 Pathway.

Authors:  Zihui Fang; Yue Wang; Zehua Wang; Meishu Xu; Songrong Ren; Da Yang; Mei Hong; Wen Xie
Journal:  Cancer Res       Date:  2020-08-21       Impact factor: 12.701

5.  Different effects of long noncoding RNA NDRG1-OT1 fragments on NDRG1 transcription in breast cancer cells under hypoxia.

Authors:  Ching-Ching Yeh; Jun-Liang Luo; Nam Nhut Phan; Yi-Chun Cheng; Lu-Ping Chow; Mong-Hsun Tsai; Eric Y Chuang; Liang-Chuan Lai
Journal:  RNA Biol       Date:  2018-12-04       Impact factor: 4.652

Review 6.  Long noncoding RNA loss in immune suppression in cancer.

Authors:  Qingsong Hu; Sergey D Egranov; Chunru Lin; Liuqing Yang
Journal:  Pharmacol Ther       Date:  2020-05-29       Impact factor: 12.310

7.  Long noncoding RNA LINC00844-mediated molecular network regulates expression of drug metabolizing enzymes and nuclear receptors in human liver cells.

Authors:  Dongying Li; Leihong Wu; Bridgett Knox; Si Chen; William H Tolleson; Fang Liu; Dianke Yu; Lei Guo; Weida Tong; Baitang Ning
Journal:  Arch Toxicol       Date:  2020-03-28       Impact factor: 5.153

8.  Long non-coding RNA CRALA is associated with poor response to chemotherapy in primary breast cancer.

Authors:  Yudong Li; Baoxiao Wang; Hongna Lai; Shunying Li; Qiuting You; Yichao Fang; Qian Li; Yujie Liu
Journal:  Thorac Cancer       Date:  2017-08-23       Impact factor: 3.500

Review 9.  Decoding LncRNAs.

Authors:  Lidia Borkiewicz; Joanna Kalafut; Karolina Dudziak; Alicja Przybyszewska-Podstawka; Ilona Telejko
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

10.  LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1.

Authors:  Zhu Kun-Peng; Ma Xiao-Long; Zhang Chun-Lin
Journal:  Oncotarget       Date:  2017-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.